Observing Long-Term Safety and Effectiveness of Octreotide Subcutaneous Depot in Adults with Acromegaly

What this Trial Is About

This research aims to collect long-term safety and effectiveness information on octreotide subcutaneous depot in patients with acromegaly in real-world settings. The study will observe patients who have started or will start this treatment, focusing on how the drug works and any side effects over up to two years. It is an observational study sponsored by Camurus AB. Participants will use commercially available octreotide subcutaneous depot treatment for up to two years while researchers monitor their health. The study does not assign treatment but observes patients under normal care conditions. The main focus will be on related adverse events, changes in hormone levels such as IGF-1 and growth hormone, and symptom changes measured by specific acromegaly questionnaires. During the study, participants will be regularly assessed for side effects and changes in their condition. Researchers will collect data on hormone levels, symptom severity using the Acromegaly Index of Severity scale, and quality of life through several questionnaires. Safety monitoring includes recording any adverse events and lab abnormalities. The total participation time may last up to two years, with ongoing observation from enrollment through the treatment period.

An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly